• Irinotecan (CPT-11): Evidence and Research Context

  2026-10-04

  Irinotecan, also known as CPT-11, is a topoisomerase I-targeting anticancer prodrug used in colorectal cancer research. This overview distinguishes reported cell and xenograft findings from stronger conclusions, explains conceptual applications, and outlines limitations involving model-specific activation, endpoint comparability, source provenance, and clinical translation.

• Protease Inhibitor Cocktail: Preserving TIE2 Biology

  2026-10-03

  Explore how a Protease Inhibitor Cocktail supports more reliable interpretation of TIE2, extracellular-vesicle, and macrophage angiogenesis studies. This evidence-focused analysis explains the EDTA-free formulation, assay relevance, and limits of protease control.

• Ivermectin: Workflow Design for Mechanistic Research

  2026-10-01

  Build reproducible Ivermectin assays by controlling solvent, exposure, and orthogonal readouts across parasite and exploratory cancer workflows. A 2024 pancreatic cancer study provides a useful model for separating phenotype from mechanism without misclassifying Ivermectin as a validated GSDMC inhibitor.

• Lapatinib Workflows for EGFR and HER2 Research

  2026-10-01

  Build a receptor-aware workflow with Lapatinib, from biochemical kinase testing to proliferation, invasion, and angiogenesis readouts. The approach separates direct EGFR/HER2 inhibition from phenotype-first findings in HER2-low or HER2-negative models, improving targeted cancer therapy research and troubleshooting.

• Bleomycin Sulfate: Practical Assay and QC Guide

  2026-09-30

  Bleomycin Sulfate provides a controllable DNA strand break inducer for cell injury, anticancer response, and pulmonary fibrosis research. This guide distinguishes product-dossier specifications from workflow recommendations and explains where the reagent should not be treated as a universal dose, pathway probe, or clinical treatment guide.

• CF10–EdU Synergy Drives Telomere Attrition

  2026-09-30

  A 2026 NAR Molecular Medicine study shows that the fluoropyrimidine polymer CF10 synergizes strongly with EdU in colorectal cancer cells, unlike the additive interaction observed with 5-fluorouracil and EdU. The combination increases EdU incorporation, DNA double-strand breaks, telomere loss, cell-cycle disruption, and mitotic catastrophe, providing a mechanistic framework for studying thymidylate stress and telomere-dependent cancer cell death.

• Anlotinib and Multitarget Angiogenesis Inhibition

  2026-09-29

  The reference study shows that anlotinib suppresses angiogenic responses driven by VEGF, PDGF-BB, and FGF-2 by inhibiting VEGFR2, PDGFRβ, FGFR1, and downstream ERK signaling. Its combination of endothelial migration, tube formation, aortic ring, and CAM assays provides a mechanistic framework for evaluating multi-target tyrosine kinase inhibitors in cancer research.

• EZ Cap™ Cas9 mRNA (m1Ψ) for MASLD Assays

  2026-09-29

  Build transient, sequence-specific LSS perturbation models with a Cap1- and m1Ψ-modified Cas9 transcript rather than relying only on small-molecule inhibition or knockdown. This workflow translates recent MASLD mechanism research into practical genome editing in mammalian cells while emphasizing controls, metabolic readouts, and RNA-quality safeguards.

• From Tau Ser356 to Translational Strategy

  2026-09-28

  A translational analysis of tau Ser356 biology, NUAK inhibition, model-specific responses, and the responsible positioning of Linagliptin (BI-1356) in exploratory research workflows.

• BIBP 3226: A Causal Probe for Cardiac Signaling

  2026-09-28

  Explore how BIBP 3226 trifluoroacetate can help researchers test receptor-level contributions to the adipose-neural axis in cardiac arrhythmia models. This article translates recent coculture findings into practical assay decisions while distinguishing NPY and NPFF pharmacology and outlining key controls.

• Anlotinib Suppresses Angiogenesis Through Three RTKs

  2026-09-27

  The study reports that anlotinib inhibits angiogenic responses induced by VEGF, PDGF-BB, and FGF-2, linking reduced endothelial migration and vessel-like structure formation to suppression of VEGFR2, PDGFRβ, FGFR1, and ERK activation. By combining cell-based, aortic-ring, and chick CAM assays, it provides convergent preclinical evidence for a multi-target anti-angiogenic mechanism, while leaving clinical efficacy and tumor-control questions unresolved.

• Caspase-3 Fluorometric Assay Kit in Ferroptosis

  2026-09-26

  The Caspase-3 Fluorometric Assay Kit can help distinguish executioner-caspase activation from other events in ferroptosis–apoptosis crosstalk. Learn how to interpret its DEVD-AFC signal alongside PARP1 findings, orthogonal readouts, and essential assay controls.

• HyperScript III RT SuperMix for CRC qPCR

  2026-09-25

  Turn colorectal cancer biomarker hypotheses into a controlled two-step qRT-PCR workflow, including practical checks for scarce RNA, GC-rich targets, and genomic DNA carryover. The integrated gDNA wiper and broad-coverage primer design are useful for exploratory validation—but the published CRC findings remain research evidence, not a clinical test.

• Ganetespib (STA-9090): Cancer Assay Workflows

  2026-09-25

  Ganetespib (STA-9090) offers a potent, non-geldanamycin approach to Hsp90 inhibition for cancer research, with practical value in dose-response testing and client-protein studies. This guide outlines a reproducible cell-assay workflow, solvent and exposure controls, and a careful way to apply insights from a norovirus secretion study without confusing distinct biological mechanisms.

• Breast Cancer Dependence on MCL-1 Is Apoptotic

  2026-09-24

  In established breast cancer models, genetic deletion or pharmacological inhibition of MCL-1 impaired tumor growth, and the antitumor effects required the pro-apoptotic proteins BAX and BAK. The findings support MCL-1’s canonical role in suppressing mitochondrial apoptosis as a central driver of breast cancer dependence, while clarifying how to interpret stemness associations and test MCL-1 inhibitors.

8009 records 3/534 page Previous Next 12345 下5页 Last page